Sulfated and nonsulfated glycosaminoglycans and glycopeptides are synthesized by kidney in vivo and incorporated into glomerular basement membranes ([35S] radioactivity and 10-15% of the total 3H radioactivity incorporated into cortex, glomeruli, or GBM was found in the GAG fraction, and the remainder (--'32% of 35S radioactivity and 85-90% of the 3H radioactivity) was found in glycopeptide fractions. Treatment of GAG fractions isolated from the three sources (cortex, glomeruli, and GBM) with nitrous acid (which degrades heparan sulfates) indicated that the majority (85%, 65%, and 87%) of the 3S radioactivity as well as the majority (60%, 50%, and 91%) of the 3H radioactivity from all three sources was degraded by this treatment. When nitrous acid-resistant GAG from GBM were subjected to digestion with Streptom ces hyaluronidase (which degrades hyaluronic acid), --6% of the H-labeled material was sensitive to this treatment. The remaining 35S-and 3H-labeled GAG isolated from GBM were digested with chondro-
itinase ABC (which degrades chondroitin sulfates A and C and dermatan sulfate). Although the ratios of the types of GAG synthesized by all three sources were similar, in GBM the ratios of IS_ to 3H-labeled GAG and of 3H-labeled glycopeptides to 3H-labeled GAG were higher (2.5 times) than those found for glomeruli. The data demonstrate the synthesis of both sulfated and nonsulfated GAG by rat kidney cortex and glomeruli and their transport to and incorporation into the GBM. Heparan sulfate is the major GAG synthesized by glomeruli, but the glomeruli also synthesize smaller amounts of hyaluronic acid and chondroitin sulfates, which are in part incorporated into GBM. In addition, the renal cortex and the glomeruli synthesize glycopeptides, some of which are sulfated, and incorporate them into GBM. Recently glycosaminoglycans (GAG) were detected by cytochemical procedures (1) in glomerular basement membranes (GBM) and subsequently isolated from purified GBM fractions (2) . Evidence has been presented that these GAG may play a role in creating the normal restrictive permeability properties of the GBM to plasma and other proteins, because increased permeability of the GBM to native ferritin (3) and "MI-labeled bovine serum albumin (unpublished data) was seen after removal of GAG by enzyme digestion in situ. To be able to assess the importance of GAG in renal physiology and pathology, it is essential to obtain information on the nature, amount, biosynthesis, and turnover of GAG in normal glomeruli in vivo, subjects about which virtually nothing is known.
In this paper we have used double-labeling with [35S]sulfate and [3H]glucosamine in vivo and specific degradative techniques followed by analysis of the degradation products. The results indicate that, under the conditions of our experiments, GAG were synthesized by glomeruli and transported to the GBM. We have also obtained a more comprehensive inventory of the glycoconjugates (GAG plus glycopeptides) present in the GBM than was available previously, and we have compared this inventory to that obtained for glomeruli and whole kidney cortex in the same experiments.
MATERIALS AND METHODS Labeling of Kidneys. Rats (125 g, Charles River) were given intraperitoneally a total of 2.5 mCi of Na235SO4 (New England Nuclear, 540-940 mCi/mmol; 1 Ci = 3.7 X 1010 becquerels) and 0.4 mCi of D- [6-3H] glucosamine (Amersham, 38 Ci/ mmol) per animal (four injections over a 10-hr period) and sacrificed 14 hr after the last injection. * Kidneys were flushed with normal saline prior to sacrifice and frozen at -20°C. Twelve kidneys were used for each glomerular analysis and 48 for GBM analysis.
Isolation of Glomeruli and GBM. Cortices were dissected from the labeled kidneys, and a sample was homogenized and set aside for glycoconjugate analysis. The remaining cortex was used to isolate glomeruli by the method of Krakower and Greenspon (5) . The purity of the glomerular fraction was monitored as described (2) . Yields ranged between 10,000 and 20,000 glomeruli per kidney (25,000-49,000 glomeruli per g of cortex). A sample of the glomeruli was set aside for glycoconjugate analysis and the GBM were isolated from the remaining glomeruli according to a modification (2) of the method of Meezan et al. (6) . In this procedure the glomeruli are first osmotically lysed, then digested with deoxyribonuclease (100 units/ml in 1 M NaCl), and finally treated with 1% deoxycholate. This protocol gives morphologically pure GBM, free from cellular contamination (1, 6) .
Determination of Specific Activity. Protein in samples of cortex, glomeruli, and GBM preparations was measured by a fluorescamine assay (7) (using IgG or albumin as a reference standard) after acid hydrolysis (in 1 M HC1 at 110°C for 24 hr).
3H or 35S radioactivity was measured in aliquots of the same preparation after digestion with Pronase and dialysis of the diAbbreviations: GAG, glycosaminoglyean(s); GBM, glomerular basement membrane(s). * A 24-hr time point was selected after the work of Barry (vol/vol) ethanol; 1.2-ml fractions were collected and 0.2 or 0.4-ml aliquots of each fraction were analyzed for radioactivity. GAG standards and labeled GAG eluted as a sharp peak with blue dextran in the void volume; glycopeptides eluted over a broad range in the retarded fractions (see Fig. 1 ).
The fractions containing GAG were pooled, lyophilized, and subjected to a series of chemical and enzymatic degradative procedures, each followed by gel filtration: (i) The GAG fraction was subjected to nitrous acid oxidation for 3 hr at room temperature (9), a procedure that selectively and completely degrades N-sulfated GAG (heparan sulfates) (10) (11) (12) . This chemical digest was then chromatographed on a Sephadex G-50 fine column (1 x 100 cm) to separate nitrous acid-resistant GAG from degradation products. Elution was with 0.1 M ammonium acetate in 20% ethanol; 1.75-ml fractions were collected, and 0.5-ml aliquots were sampled for radioactivity. ( ii) The residual GAG fraction was pooled and treated with Streptomyces hyaluronidase (Miles; 5 turbidity-reducing units/ml in 3.0 ml of 0.02 M sodium acetate buffer, pH 5.0) for 24 hr at 37°C with fresh enzyme added after 12 hr. This enzyme specifically degrades hyaluronic acid (13) . The enzyme-resistant GAG and hyaluronidase digestion products were separated by gel filtration as described above in step (Fig. 1) shows a 2.5 times higher GAG/3H-GAG) in GBM compared to cortex. The dat either a higher amount of newly synthesized sulfate( the GBM or a higher degree of sulfation of individ species in GBM. When the ratio of 3H-glycopeptides/ is compared for cortex, glomeruli, and GBM, this value to be 2.5 times greater for GBM, suggesting a relativ ment of 3H-glycopeptides in this structure.
Distribution of Label in Specific GAG. Hepara When the GAG fractions that eluted in the void volt the Sephadex G-50 column (Fig. 1) were subjected 1 acid oxidation and rechromatographed (Fig. 2) , the m both the 'S-and 3H-GAG from all three sources was C therefore, it consists of heparan sulfate. In the case of derived from cortex, glomeruli, and GBM, 85%, 68%, Representative example from labeled glomeruli, showing separation of resistant GAG and degradation products after nitrous acid oxidation. Total GAG remaining after sampling for radioactivity (see Fig. 1B) were pooled, subjected to nitrous acid treatment, and rechromatographed on Sephadex G-50 (1 x 100 cm). Fractions (1.75 ml) were collected, and 0.5-ml aliquots were assayed for radioactivity. 35S_
Labeled digestion products eluted as two major peaks and 3H-labeled eluted as one major peak. Labeled GAG resistant to nitrous acid eluted in the void volume (fractions [16] [17] [18] [19] [20] [21] [22] [23] [24] . Thin line, 35S radioactivity; thick line, 3H radioactivity.
respectively, of the label originally present in GAG eluted with 1.5 the degradation products ( Fig. 3 ) were digested ¢^, with chondroitinase ABC and rechromatographed (Fig. 4) Example from labeled glomeruli, showing separation of nitrous acid-and hyaluronidase-resistant GAG from hyaluronidase digestion products. Nitrous acid-resistant GAG remaining after aliquots had been removed forradioactivity assay (see Fig. 2 ) were pooled, digested with Streptomyces hyaluronidase, and rechromatographed on Sephadex G-50 as in Fig. 2 . Fractions (1.75 ml) were collected and radioactivity was determined in 0.5-ml samples. 3H-Labeled digestion products eluted in one major peak. Enzyme-resistant m5S-and 3H-GAG eluted in the void volume (fractions [16] [17] [18] [19] [20] [21] [22] [23] [24] . Thin line, 35S radioactivity; thick line, 3H radioactivity.
sulfate [which is not degraded by any of the procedures applied (8)]. A similar unidentified chemical-and enzyme-resistant fraction has been found in other tissues (8, 15) .
DISCUSSION
In this study we have labeled in vivo, biosynthetically, kidney cortex, glomeruli, and GBM with [35S]sulfate and [3H]glucosamine and have identified the radioactive macromolecules synthesized with these precursors. The results demonstrate the incorporation of label into several GAG species and into glycopeptides isolated from all three sources. In all cases, heparan sulfate is the major labeled GAG present, because the majority of both the 35S and 3H radioactivity is associated with this GAG (on the basis of susceptibility to nitrous acid oxidation). Small amounts of newly synthesized nonsulfated GAG (hyaluronic acid) and sulfated GAG other than heparan sulfate (i.e., chondroitin sulfates A or C or dermatan sulfate) are also present in these preparations (on the basis of susceptibility of 3H-labeled material to Streptomyces hyaluronidase and on the basis of susceptibility of 3S-and 3H-labeled material to chondroitinase ABC, respectively). This biosynthetic profile correlates well with the compositional profile obtained previously by chemical analysis of GAG isolated from GBM in which heparan sulfate was found to be the major GAG present in GBM (2) . The previous data (obtained by cellulose acetate electrophoresis) also suggested that a small amount of hyaluronic acid may be 2.0 Representative example from labeled cortex showing separation of GAG resistant to nitrous acid, hyaluronidase, and chondroitinase ABC from chondroitinase ABC digestion products. Hyaluronidase-resistant GAG, after sampling for radioactivity, were pooled, treated with chondroitinase ABC, and rechromatographed on Sephadex G-50 as in Fig. 2 . Fractions (1.75 ml) were collected and 0.5-ml aliquots were taken for radioactivity assays. 35S_ and 3H-labeled digestion products coeluted as one major peak. Unidentified material resistant to all three treatments eluted in the void volume (fractions [16] [17] [18] [19] [20] [21] [22] [23] [24] (16) .
In addition to GAG synthesis, synthesis of glycopeptides by cortex and glomeruli and the incorporation of these products into the GBM in vivo has been demonstrated here. We have found that some of the glycopeptides are sulfated, as demonstrated by the fact that ='A of the 'S label incorporated into the GBM was associated with glycopeptides. Although sulfated glycopeptides have been detected in other tissues, especially in brain (17) , their presence in the glomerulus and in GBM has not previously been reported.
A surprising finding is that the profiles of labeled GAG extracted from cortex, glomeruli, and GBM are similar in that the major GAG synthesized are heparan sulfate, chondroitin sulfates, and hyaluronic acid, with heparan sulfate predominating in all three. One might expect relatively more label to be incorporated into chondroitin sulfates and hyaluronic acid in the whole cortex due to the large amount of interstitial connective tissue matrix present; however, such was not the case. At present it is not possible to determine whether the data reported reflect different amounts or different turnover rates for the types of GAG found in cortex and glomeruli. Further experiments-autoradiography for localization and double labeling at different time points to study turnover-should clarify this issue.
Notwithstanding the overall similarity of the type and ratios of labeled GAG found in cortex, glomeruli, and GBM (heparan sulfate >> chondroitin sulfates and hyaluronic acid), there are some distinct differences in the radioactivity distribution patterns obtained from the three sources. Notable were the findings that there was a 2.5 times higher ratio of 35S-GAG/3H-GAG in GBM compared to whole cortex. In addition, there was a 2.5 times higher ratio of 3H-glycopeptides/3H-GAG in the GBM as opposed to glomeruli or whole cortex. With the approach used we cannot determine the nature of the 3H-labeled glycopeptide molecules. In principle, the label could be associated with either collagenous or noncollagenous components of the GBM. Because basement membrane collagens are present in a procollagen-like form (18) , and if the situation is the same for basement membrane (types IV and V) as for interstitial (type I) collagen (19) , the glucosamine label could be associated with the NH2-or COOH-terminal extensions of the procollagen molecules. In addition, several noncollagenous glycoproteins (e.g., fibronectin, laminin) have been found to be associated with many basement membranes, including the GBM (20, 21) .
Up to now there has been very little work on the synthesis of GAG in the kidney. The most extensive study carried out to date was that of Barry and Bowness (4), who compared the incorporation of label into GAG in kidney cortex with that in medulla after labeling in vivo with [35S]sulfate and [14C]glucose. They also found heparan sulfate to be the major GAG synthesized in medulla as well as cortex, with smaller amounts of hyaluronic acid, chondroitin sulfates, and dermatan sulfate detected. Cohen (22) has studied GBM synthesis in vitro in isolated glomeruli and has reported incorporation of [3S]sulfate into uronic acid-containing material extracted (with 8 M urea) from GBM; however, she did not determine incorporation into individual GAG species or into glycopeptides.
Cell Biology: Lemkin and Farquhar a I A number of studies have been done on the synthesis of GAG and their assumed incorporation into basement membranes in other tissues, primarily embryonic tissues such as lens, neural tube, notochord (23) , cornea (24) , and salivary (25) and mammary (26) glands. All these tissues were found to synthesize various amounts of both heparan sulfate and chondroitin sulfate, and most also synthesized hyaluronic acid. In these embryonic systems a role has been postulated for basement membrane GAG in morphogenesis and development. In all cases the association between GAG and basement membranes was inferred from combined biosynthetic (autoradiographic) and cytochemical observations rather than demonstrated on isolated basement membrane fractions because satisfactory basement membrane fractions have not yet been prepared from these tissues.
Previous cytochemical studies have demonstrated that heparan sulfate is a major component of anionic sites localized in the laminae rarae (interna and externa) of GBM (27) because treatment of GBM with heparitinase (which specifically digests heparan sulfate) removes the anionic sites as detected by binding of cationized ferritin (1) . The location of hyaluronic acid and chondroitin sulfates in GBM is not known. Treatment of GBM with hyaluronidase or chondroitinase ABC has no detectable effect on the anionic sites '(with cationized ferritin used as a probe) (1). This could indicate that these GAG have a different location than heparan sulfate or, alternatively, that, although associated with the anionic sites, these GAG do not contribute significantly to their net charge. Accordingly, their removal would not interfere with cationized ferritin binding and would not be detected.
The finding that the specific radioactivity of the GBM for 35S and 3H is =11% and =28% of the corresponding values for glomeruli raises the question as to the location of the remaining non-GBM-associated glycoconjugates in the glomerulus. Assuming that minimal amounts of GAG and glycopeptides are lost during the isolation of GBM, there must be a considerable pool of newly synthesized GAG and glycopeptides associated with glomerular cells or cell surfaces whose distribution is not known at present. In the future it will be of interest to localize, identify, and characterize further these newly synthesized glomerular glycoconjugates.
